HoFH in children: Key diagnostic challenges and the case for early detection

By Lisa Marie BasileFact-checked by Barbara BekieszPublished February 27, 2026

Industry Buzz

Diagnosis relies on lipid screening, a detailed family history, and, when available, genetic testing to confirm inherited risk. Early detection is critical because atherosclerotic changes can begin in childhood, even when patients appear otherwise healthy.

—Octavia Schlueter, MSN, RN

Homozygous familial hypercholesterolemia (HoFH) is a severe form of familial hypercholesterolemia (FH), a genetic metabolic disease leading to extremely elevated low-density lipoprotein cholesterol (LDL-C) levels from birth. High LDL-C increases the risk of atherosclerotic cardiovascular disease (ASCVD) and early mortality, but sometimes it’s a silent killer.

The hidden lifetime LDL-C burden driving early ASCVD

In heterozygous FH, or HeFH (in which one allele is affected), patients are 20 times more likely to develop ASCVD without treatment. Homozygous FH (HoFH) is rarer, requiring two alleles. This form is more severe and can cause cardiovascular disease in children under the age of 10.^[] It affects about one in 300,000 people.^[]

According to a review published in Current Opinion in Lipidology, cardiovascular risk in HoFH is driven not solely by LDL cholesterol levels at a single point in time, but by cholesterol burden over time, or the total lifetime exposure to LDL cholesterol.^[] The authors found that this cumulative exposure is a stronger predictor of ASCVD than LDL levels on their own.

The problem is that many children go undiagnosed because high LDL-C levels can go unseen. According to the Family Heart Foundation, these pediatric patients (especially those who fall short of the most severe cases of HoFH) aren’t being diagnosed and are missing out on life-saving treatments. These are the ones who don’t show physical symptoms of HoFH—which is where lipid panels, family history, and genetic testing come into play.^[]

“High cholesterol does not necessarily cause immediate harm, but the goal is early detection to promote awareness and allow for early intervention to prevent long-term consequences,” says Michael Glazier, MD, Chief Medical Officer at Bluebird Kids Health.

Diagnosing hypercholesterolemia

Dr. Glazier says the American Academy of Pediatrics recommends universally screening all children for hypercholesterolemia between the ages of 9 and 11 and then again between 17 and 21 years. “This is done as a point of care test in our office, and the child does not have to be fasting to do it,” he says.

But focusing on the family is just as helpful as screening. "The first step in detecting hypercholesterolemia is taking a detailed family history. As a pediatrician, it is important for us to focus not just on the child in front of us, but also on the family as well. If available, family medical history is an important part of how we approach care,” Dr. Glazier says.

“If there is a family history of hypercholesterolemia or premature cardiovascular disease, particularly if it was detected in a relative at a young age, we will often screen children many years prior to this, often between 2 and 8, with a fasting lipid panel.” Infant screening is also a possibility, although there is no validated test for doing so. There is also little known about treating a child with HoFH under the age of 5.^[]

What should you be looking out for? Octavia Schlueter, MSN, RN, a pediatric nurse practitioner and director at Collaborating Docs, says FH can be identified in a child with significantly elevated LDL-Clevels—often above 160 mg/dL in children with a family history of premature cardiovascular disease, or above 190 mg/dL without a known history.

“Diagnosis relies on lipid screening, a detailed family history, and, when available, genetic testing to confirm inherited risk,” Schlueter says. “Early detection is critical because atherosclerotic changes can begin in childhood, even when patients appear otherwise healthy.”

When clinicians can properly identify FH, families can make lifestyle interventions and start pharmacologic therapy such as statins. “These can substantially reduce long-term cardiovascular risk and shift the focus from reactive treatment in adulthood to proactive prevention starting in childhood,” she says.

SHARE THIS ARTICLE